INVESTIGATING THE LONGITUDINAL PATTERNS OF USE AND COMPARATIVE EFFECTIVENESS OF BETA BLOCKER THERAPY IN THE HEMODIALYSIS POPULATION

Public Deposited

Downloadable Content

Download PDF
Request Version for Screen Reader
Last Modified
  • March 20, 2019
Creator
  • Assimon, Magdalene
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
Abstract
  • United States hemodialysis patients experience high rates of cardiovascular mortality. Approximately 50% of deaths are due to cardiovascular disease. In the general population, beta blocker treatment improves clinical outcomes in a range of cardiovascular conditions. However, the cardioprotective benefit of beta blocker therapy has never been evaluated by large randomized trials in individuals receiving maintenance hemodialysis therapy, a population with special drug dosing considerations. Pharmacologic and pharmacokinetic differences across individual beta blockers may alter drug efficacy and safety profiles in the setting of end-stage renal disease. Using the clinical research database of a large United States dialysis provider linked with the United States Renal Data system registry we assembled a cohort of maintenance hemodialysis with Medicare insurance coverage who initiated beta blocker therapy from 2007 – 2012 to: 1) assess long-term beta blocker utilization patterns in the hemodialysis population, 2) examine the association between beta blocker adherence versus non-adherence (proportion of days covered (PDC) ≥ 80% versus PDC < 80%) and all-cause mortality, and 3) evaluate the association between carvedilol versus metoprolol initiation and 1-year all-cause and cardiovascular mortality. First, we found that carvedilol and metoprolol were the most commonly initiated beta blockers (79.7% of all beta blocker new-users). After beta blocker initiation, therapy cessation (i.e. discontinuation) and re-initiation were relatively common. Second, we found that beta blocker adherence (versus non-adherence) was associated with lower all-cause mortality (PDC ≥ 80% versus < 80% measured using pharmacy claims: adjusted hazard ratio (HR) [95% confidence interval (CI)] = 0.84 [0.79, 0.90]). Finally, we found that carvedilol (versus metoprolol) initiation was associated with higher all-cause (adjusted HR [95% CI] = 1.09 [1.02, 1.16]) and cardiovascular mortality (adjusted HR [95% CI] = 1.19 [1.08, 1.30]). The potential mechanism for the observed mortality association may be the increased rate of intradialytic hypotension observed after carvedilol (versus metoprolol) initiation. Our findings provide insights into: 1) the longitudinal patterns of beta blocker utilization among individuals receiving maintenance hemodialysis therapy, 2) the association between beta blocker adherence and all-cause mortality, and most importantly, 3) provide important evidence to guide beta blocker prescribing in hemodialysis population the absence of clinical trial data.
Date of publication
Keyword
DOI
Resource type
Rights statement
  • In Copyright
Advisor
  • Heiss, Gerardo
  • Flythe, Jennifer
  • Brookhart, M. Alan
  • Layton, J. Bradley
  • Fine, Jason
Degree
  • Doctor of Philosophy
Degree granting institution
  • University of North Carolina at Chapel Hill Graduate School
Graduation year
  • 2017
Language

Relations

Parents:

This work has no parents.

Items

Thumbnail Title Date Uploaded Visibility Actions
file details Assimon_unc_0153D_17461.pdf 2019-04-05 Public Download
file details PREMIS_Events_Metadata_0_034f5a03-c237-4d24-bfa9-a4a2dfdee78b.txt 2019-04-05 Public Download
file details original_metadata_file_034f5a03-c237-4d24-bfa9-a4a2dfdee78b.xml 2019-04-05 Public Download